Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Other

Dupont Pharmaceuticals Company

Charles G Clark

Donald J P Pinto

Patrick Y S Lam

John Matthew Fevig

Qi Han

Mimi Lifen Quan

James Russell Pruitt

William R Ewing

Leon M Smith, Ii

Celia Dominguez

Wu Yang

Jennifer X Qiao

Yufeng Wang

Karen Anita Rossi

Tammy C Wang

Yoon T Jeon

James R Corte

Paul Joseph Gilligan

Michael J Orwat

Ruth Richmond Wexler

Jacques Y Roberge

Robert A Galemmo, Jr

Irina C Jacobson

Timur Gungor

Rejean Ruel

Jiacheng Zhou

R Michael Lawrence

James A Johnson

Timothy F Herpin

Hui-Yin Li

Joanne M Smallheer

Pasquale N Confalone

Zulan Pi

Patrick Y Lam

Renhua Li

Renhau Li

Carl Thibeault

Hannguang J Chao

Joseph Cacciola

Alexandre L'Heureux

Robert P Rehfuss

Huji Tuerdi

Gilles Bouthillier

Yalei Liu

Dora M Schnur

Patrick Yuk Sun Lam

Amy Han

Nicholas Ronald Wurtz

Philip Ma

Donald J Pinto

Andrew K Dilger

Ellen K Kick

Carol Hui Hu

Tasir Shamsul Haque

Lynette May Oh

Scott A Shaw

Pravin Sudhakar Shirude

Sutjano Jusuf

Meriah Neissel Valente

Benjamin P Vokits

Jack D Clark

Amit Kumar Chattopadhyay

Balaji Seshadri

Michael R Lawrence

Indawati DeLucca

Lucius T Rossano

Barbara F Clark

Thomas E Richardson

Chris Teleha

Donald Jp Pinto

Donald JP Pinto

Leon M Smith Ii

Leon M Ii Smith

Patrick YS Lam

Ii Leon M Smith

Timothy Herpin

Jacques Yves Roberge

Alexandre L L'HEUREUX

The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

Triazolopyridine inhibitors of myeloperoxidase and/or EPX

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders. 

[object Object]

The present invention provides compounds of Formula (I): (Formula (I)) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments. 

Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments. 

Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Cyclic P1 linkers as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

The present invention provides indole compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables ring A, X, X, X, X, R, and Rare as defined herein. These compounds are selective inhibitors of the human P2Yreceptor which can be used as medicaments.

The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

The present application describes pyrazolobenzamides and derivatives thereof of Formula I:P-P-M-MIor pharmaceutically acceptable salt forms thereof. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Pyrazolobenzamides and derivatives as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Guanidine mimics as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I:or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Guanidine mimics factor Xa inhibitors

The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Nitrogen containing heterobicycles as factor Xa inhibitors

A quilting frame apparatus is disclosed, which provides a user with a more efficient work area than is provided with traditional quilting frames. The quilting frame apparatus comprises concentric rectangular outer and inner frames. The outer frame is constructed from four elongate members attached in a mortise-and-tenon arrangement at each of its four corners and secured by wingnuts. The quilting frame may be adjusted at different angles to suit the user. The apparatus may also be folded for convenient storage.

Quilting frame apparatus

Growing community of inventors

Cherry Hill, NJ, United States of America

Charles G Clark